These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35806873)

  • 21. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus.
    Piga M; Floris A; Cappellazzo G; Chessa E; Congia M; Mathieu A; Cauli A
    Arthritis Res Ther; 2017 Nov; 19(1):247. PubMed ID: 29126432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
    Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
    Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience.
    Tani C; Elefante E; Signorini V; Zucchi D; Lorenzoni V; Carli L; Stagnaro C; Ferro F; Mosca M
    RMD Open; 2019; 5(2):e000916. PubMed ID: 31275608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
    Hao Y; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Zhang Z
    Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35241499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Burden of lupus activity on health care resources utilization in Buenos Aires, Argentina.
    Alvarado RN; Alle G; Tobar-Jaramillo MA; Palomino LC; Cáceres AG; Rosa JE; Machnicki G; Zazzetti F; Soriano E; Scolnik M
    Lupus; 2023 Dec; 32(14):1656-1665. PubMed ID: 37955177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups.
    Massias JS; Smith EMD; Al-Abadi E; Armon K; Bailey K; Ciurtin C; Davidson J; Gardner-Medwin J; Haslam K; Hawley DP; Leahy A; Leone V; McErlane F; Mewar D; Modgil G; Moots R; Pilkington C; Ramanan AV; Rangaraj S; Riley P; Sridhar A; Wilkinson N; Beresford MW; Hedrich CM
    Lupus; 2020 Apr; 29(5):474-481. PubMed ID: 32233733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus.
    Na Nakorn K; Piyaphanee N; Sukharomana M; Pinpatanapong R; Charuvanij S
    Clin Rheumatol; 2023 Jun; 42(6):1655-1664. PubMed ID: 36780064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials.
    Parodis I; Lindblom J; Levy RA; Zen M; Cetrez N; Gomez A; Oon S; Henning C; Khamashta M; Quasny HA; Chauhan D; Askanase A; van Vollenhoven R; Nikpour M
    Lancet Rheumatol; 2024 Aug; ():. PubMed ID: 39208825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus.
    Golder V; Kandane-Rathnayake R; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake BMDB; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Lau CS; Nikpour M; Hoi A; Morand EF;
    J Rheumatol; 2024 Aug; 51(8):790-797. PubMed ID: 38490668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
    Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of systemic lupus erythematosus (SLE) Disease Activity Score and SLE Disease Activity Index 2000-based remission states in patients with SLE on damage accrual.
    Chitpet P; Chaiamnuay S; Narongroeknawin P; Asavatanabodee P; Leosuthamas P; Pakchotanon R
    Int J Rheum Dis; 2023 Dec; 26(12):2509-2516. PubMed ID: 37875327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).
    van Vollenhoven R; Voskuyl A; Bertsias G; Aranow C; Aringer M; Arnaud L; Askanase A; Balážová P; Bonfa E; Bootsma H; Boumpas D; Bruce I; Cervera R; Clarke A; Coney C; Costedoat-Chalumeau N; Czirják L; Derksen R; Doria A; Dörner T; Fischer-Betz R; Fritsch-Stork R; Gordon C; Graninger W; Györi N; Houssiau F; Isenberg D; Jacobsen S; Jayne D; Kuhn A; Le Guern V; Lerstrøm K; Levy R; Machado-Ribeiro F; Mariette X; Missaykeh J; Morand E; Mosca M; Inanc M; Navarra S; Neumann I; Olesinska M; Petri M; Rahman A; Rekvig OP; Rovensky J; Shoenfeld Y; Smolen J; Tincani A; Urowitz M; van Leeuw B; Vasconcelos C; Voss A; Werth VP; Zakharova H; Zoma A; Schneider M; Ward M
    Ann Rheum Dis; 2017 Mar; 76(3):554-561. PubMed ID: 27884822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care.
    Castrejón I; Tani C; Jolly M; Huang A; Mosca M
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-85-95. PubMed ID: 25365095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.
    Ho A; Magder LS; Barr SG; Petri M
    Arthritis Rheum; 2001 Oct; 44(10):2342-9. PubMed ID: 11665975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of menopause on disease activity in systemic lupus erythematosus.
    Urowitz MB; Ibañez D; Jerome D; Gladman DD
    J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials.
    Parodis I; Emamikia S; Gomez A; Gentline C; Arkema EV; Chatzidionysiou K; van Vollenhoven RF
    Lancet Rheumatol; 2019 Nov; 1(3):e163-e173. PubMed ID: 38229393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort.
    Tani C; Vagelli R; Stagnaro C; Carli L; Mosca M
    Lupus Sci Med; 2018; 5(1):e000234. PubMed ID: 29531772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus.
    Nived O; Jönsen A; Bengtsson AA; Bengtsson C; Sturfelt G
    J Rheumatol; 2002 Jul; 29(7):1398-400. PubMed ID: 12136895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The new 2019-EULAR/ACR classification criteria specific domains at diagnosis can predict damage accrual in 670 childhood-onset systemic lupus erythematosus patients.
    Pitta AC; Silva CA; Insfrán CE; Pasoto SG; Trindade VC; Novak GV; Sakamoto AP; Terreri MT; Pereira RM; Magalhães CS; Fonseca AR; Islabão AG; Assad AP; Buscatti IM; Elias AM; Piotto DP; Ferriani VP; Carvalho LM; Rabelo Junior CN; Marini R; Sztajnbok FR; Sacchetti SB; Bica BE; Moraes AJ; Robazzi TC; Lotufo S; Cavalcanti AS; Naka EN; Carneiro-Sampaio M; Bonfá E; Aikawa NE;
    Lupus; 2021 Dec; 30(14):2286-2291. PubMed ID: 34689652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.